OS-01
Also known as Peptide 14, Peptide OS-01, Decapeptide-52, O-304
OS-01 is the first peptide scientifically proven to reduce cellular senescence—the accumulation of aged, dysfunctional cells that drive visible aging and disease—by directly targeting this fundamental aging mechanism in skin. Laboratory studies show OS-01 reduces senescence marker CDKN2A by 50% in human skin samples and reversed the biological age of ex vivo skin samples by 2.5 years in just 5 days, an unprecedented achievement demonstrating genuine cellular age reversal rather than cosmetic concealment.
Route
Topical application
Dose range
See table
Frequency
Twice daily (Morning and Night)
Cycle length
12+ weeks for measurable changes in skin "biological age."
Overview
OS-01 is the first peptide scientifically proven to reduce cellular senescence—the accumulation of aged, dysfunctional cells that drive visible aging and disease—by directly targeting this fundamental aging mechanism in skin. Laboratory studies show OS-01 reduces senescence marker CDKN2A by 50% in human skin samples and reversed the biological age of ex vivo skin samples by 2.5 years in just 5 days, an unprecedented achievement demonstrating genuine cellular age reversal rather than cosmetic concealment.
Beyond reducing senescent burden, OS-01 boosts cellular renewal, increases collagen and hyaluronan synthase expression, reduces inflammation, and improves skin barrier function, texture, and radiance. Clinical trials confirmed superior results with OS-01 included versus vehicle alone, with measurable improvements in wrinkle depth and skin elasticity. Applied topically, especially around delicate periocular skin which naturally accumulates senescence with age, OS-01 offers the first senotherapeutic approach to literally reverse skin’s biological age. For anyone over 40 noticing aging signs, OS-01 represents a scientifically unprecedented opportunity to slow and reverse cellular aging at its root mechanism.
Studied benefits
- A longevity peptide designed to reduce the "biological age" of the skin
- It works by targeting senescent cells (zombie cells) and promoting DNA repair
- It strengthens the skin barrier, increases collagen production, and improves overall skin smoothness and elasticity
Reported side effects
- Primarily used topically
- generally well-tolerated
- Rare instances of mild skin irritation or redness in individuals with highly sensitive skin
Protocol
Application Schedule (Topical)
Educational reference only. Not medical advice. Research compounds are not approved for human use. Full disclaimer.
| Phase | Application Method | Frequency | Log |
|---|---|---|---|
| Initial Research | Face/Neck Topical | Twice Daily | + Log |
| Maintenance | Face/Neck Topical | Once Daily | + Log |
Frequency
Twice daily (Morning and Night).
Timing
Apply to clean, dry skin prior to occlusive moisturizers.
Cycle length
12+ weeks for measurable changes in skin "biological age."
Context
Lifestyle considerations
Maintain a diet rich in essential fatty acids and antioxidants to support the dermal barrier and the cellular repair signaling promoted by this senolytic peptide. Ensure 7–9 hours of nightly sleep to allow the skin to enter its peak regenerative phase, where the peptide’s focus on reducing senescent cell burden is most effective. Maintain a consistent skincare routine including daily moisturizers and broad-spectrum SPF to prevent UV-induced cellular aging. Avoid smoking and high sugar intake, as these factors contribute to the accumulation of senescent cells and skin sagging that the peptide seeks to reverse.
Evidence
Research summaries
Double-blind, vehicle-controlled clinical investigation of peptide OS-01 (pDPK) for skin health
Findings: Locks in moisture, cuts wrinkles round eyes, boosts glow and texture.
OS-01, mitophagy trigger (cleans old cell parts), in cream. 12-week face-half trial, 22 people: OS-01 side sealed water loss better, wrinkles eased (3D scans), texture/radiance up big. Both sides helped but OS-01 superior. Old cells cleared for fresh skin. Like house spring clean: smoother, dewier face for teen glow-up.
Read the study ↗Clinical efficacy of OS-01 peptide formulation in reducing the signs of aging in the periorbital region
Findings: 17% less water loss, 32% hydration jump, 25% elasticity gain, fades puff/dark circles.
Eye cream trial 12 weeks: TEWL down 17%, hydration +32%, firmness +10%, bounce +25%. Lines/puff/circles shrunk; 95% saw better look. Safe powerhouse for tired eyes from screens/sleep.
Read the study ↗OS-01 Peptide Topical Formulation Improves Skin Barrier Function
Findings: Strengthens barrier vs. dryness, radiance boost, anti-senescence cleanup.
Builds barrier, fights dehydration/wrinkles via cell refresh. Youthful skin sans irritation.
Read the study ↗More references (4)
- OS-01 Peptide Topical Formulation Improves Skin Barrier Function and Reduces Systemic Inflammation: A Pilot 12-Week Clinical Trial, 2025
- A Senotherapeutic Peptide (OS-01) Counteracts Age-Related Skin Changes and Influences Biological Age, 2025
- Targeting Senescent Cells in the Skin to Improve Systemic Longevity Outcomes, 2024
- Mechanisms of Senotherapeutic Peptides in Skin Rejuvenation, 2022
Identification
Chemistry
- common names
- OS-01, Peptide 14, Peptide OS-01, Decapeptide-52, O-304
- cas
- 1261289-04-6
- formula
- C₁₆H₁₁Cl₂N₃O₂S
- molecular weight
- 380.2 Da
- sequence
- Not publicly disclosed in peer-reviewed literature; proprietary composition protected by OneSkin Technologies patent portfolio; described only as a 10-amino acid (decapeptide) or 14-amino acid sequence depending on formulation variant
- source
- Synthetic; designed through rational drug discovery specifically to activate AMPK without requiring AMP-dependent mechanisms
- biosynthesis
- Laboratory-synthesized using chemical peptide synthesis methods; not derived from natural peptides or proteins
- type
- Linear peptide (10 or 14 amino acids depending on formulation variant)
Keep exploring
Related peptides
5-Amino-1MQ
5-amino-1-methylquinolinium · NNMTi
- Route
- Subcutaneous
- Dose
- 2.5 mg – 5 mg
- Cycle
- 10–20 days (based on a single 50 mg vial)
Acetyl Hexapeptide-3 (Argireline)
Argireline · Acetyl Hexapeptide-3
- Route
- Topical
- Dose
- —
- Cycle
- 30 days for primary assessment
AHK (Tripeptide-3)
Tripeptide-3 · AHK
- Route
- Topical
- Dose
- 500 mcg – 1 mg
- Cycle
- 8–12 weeks
AHK-Cu
GHK-Cu · Copper Tripeptide-1
- Route
- Topical
- Dose
- —
- Cycle
- —